|1.||Nasehi, Mohammad: 4 articles (02/2016 - 03/2014)|
|2.||Zarrindast, Mohammad-Reza: 4 articles (02/2016 - 03/2014)|
|3.||Khakpai, Fatemeh: 2 articles (06/2015 - 02/2015)|
|4.||Gaven, Florence: 2 articles (09/2014 - 01/2013)|
|5.||Giannoni, Patrizia: 2 articles (09/2014 - 01/2013)|
|6.||Claeysen, Sylvie: 2 articles (09/2014 - 01/2013)|
|7.||Khodayar, Ebrahim: 1 article (02/2016)|
|8.||Oryan, Shahrbanoo: 1 article (02/2016)|
|9.||Kafi, Faezeh: 1 article (06/2015)|
|10.||Tabatabaie, Maryam: 1 article (02/2015)|
|1.||Amnesia (Dissociative Amnesia)
02/01/2016 - "Interestingly, RS67333 exerted a dual effect on ACPA-induced behaviors, potentiating and restoring amnesia caused by the subthreshold and effective doses of ACPA, respectively. "
02/01/2016 - "Intra-NAc shell administration of ACPA (selective cannabinoid CB1 receptor agonist 0.006 µg/rat) and RS23597 (5-HT4 receptor antagonist 0.01 µg/rat), immediately after training, decreased emotional memory consolidation, suggesting a drug-induced amnesia, whereas post-training intra-NAc shell microinjections of RS67333 (5-HT4 receptor agonist 0.016 µg/rat) increased emotional memory consolidation. "
06/01/2015 - "In addition, intra-CA3 injection of Y-25130, RS67333, and RS23597-190 heighten the ACPA-induced amnesia and head dip counts while did not alter head dip latency and locomotor activity. "
02/05/2015 - "The results also showed that post-training intra-CA1 injection of a sub-threshold dose of RS67333 (6.25 ng/mouse) or RS23597 (0.1 ng/mouse) could heighten MK801 induced amnesia and decrease locomotor activity, but it did not alter head-dip counts and head-dip latency. "
01/01/2013 - "Chronic administration of RS 67333 decreased concomitantly the number of amyloid plaques and the level of Aβ species. "
01/01/2012 - "When RS-67333 was injected for 10 days in Tg2576 mice, a model of amyloid-β peptide (Aβ) deposition, there was an increase in hippocampal levels of sAβPPα, C-terminal fragment α, and MMP-9, as well as a decrease in hippocampal senile plaque number and levels of the 40 amino acid peptide, Aβ40. "
|3.||Alzheimer Disease (Alzheimer's Disease)
09/09/2014 - "This effect has generated great interest in RS67333 as a potential treatment for Alzheimer's disease (AD). "
01/01/2013 - "Early administration of RS 67333, a specific 5-HT4 receptor agonist, prevents amyloidogenesis and behavioral deficits in the 5XFAD mouse model of Alzheimer's disease."
|4.||Memory Disorders (Memory Loss)
|1.||5-HT4 Serotonin Receptors
|3.||diazenedicarboxylic acid bis(N'-methylpiperazide)
|4.||CB1 Cannabinoid Receptor (CB1 Receptor)
|5.||Dizocilpine Maleate (Dizocilpine)
|6.||Amyloid (Amyloid Fibrils)